Recent findings from the world’s largest randomized controlled trial (RCT) have dashed hopes that the meningococcal B vaccine 4CMenB (Bexsero®) could prevent gonorrhea. Presented at the Conference on Retroviruses and Opportunistic Infections, the research from Griffith University and the Kirby Institute at UNSW Sydney confirmed that the vaccine does not protect against gonorrhea, contradicting earlier optimism from observational studies.
The study, published on February 25, 2026, involved 587 participants with a history of gonorrhea or syphilis. Over two years, the incidence of gonorrhea was nearly identical between the vaccine and placebo groups: 48.1 cases per 100 person-years in the vaccine group versus 47.8 in the placebo group. This resulted in a vaccine efficacy of –0.5%.
Disappointment in the Scientific Community
Lead investigator Prof. Kate Seib expressed the scientific community’s disappointment: “These results were unexpected given the observational findings and somewhat disappointing considering the need for a gonorrhea vaccine.” The data clearly showed that 4CMenB was ineffective in reducing gonorrhea incidence among participants.
This outcome aligns with the French DOXYVAC RCT, which also showed a non-significant reduction in gonorrhea incidence. Earlier observational studies had suggested a 33–40% effectiveness, leading to the UK’s decision to roll out the vaccine for high-risk men in 2025. However, these studies often fail to account for variables like behavior and partner networks, which can skew results.
Implications for Public Health Programs
The UK’s program, launched in August 2025, is now under reassessment. Galicia, Spain, had been the first to implement a vaccination program aimed at preventing gonorrhea. Meanwhile, the U.S. Centers for Disease Control and Prevention (CDC) never recommended 4CMenB for gonorrhea prevention, focusing instead on meningococcal disease.
The 4CMenB vaccine, approved in about 40 countries, has significantly impacted global health by reducing deaths and disabilities caused by N. meningitidis. However, with over 82 million global gonorrhea cases annually and rising antimicrobial resistance, the need for a dedicated gonorrhea vaccine remains critical.
Looking Forward: Prevention and Future Research
CDC experts emphasize proven prevention methods: consistent condom use, regular STI testing and treatment, partner notification, and doxycycline post-exposure prophylaxis for select high-risk groups. Until a dedicated vaccine is developed, these strategies remain the best defense against gonorrhea.
The recent trials underscore the complexity of developing a vaccine for sexually transmitted infections, where behavioral factors play a significant role. The scientific community continues to seek innovative solutions, but as of March 2, 2026, gonorrhea remains not vaccine-preventable.
As researchers continue to explore new avenues for vaccine development, public health officials must focus on education and prevention to manage the spread of gonorrhea effectively. The quest for a viable vaccine continues, highlighting the importance of ongoing research and international collaboration in combating this persistent public health challenge.
